Sign in Sign up for free

Panbela Therapeutics Income

What is the Income of Panbela Therapeutics?

The Income of Panbela Therapeutics Inc. is -$23.51

What is the definition of Income?

Net income available for common shareholders equals net income minus preferred dividends paid.

ttm (trailing twelve months)

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Income of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics

What does Panbela Therapeutics do?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Companies with income similar to Panbela Therapeutics